Delisting risk
Revelation Biosciences (REVB)
Develops Gemini immunomodulators for acute kidney injury and chronic kidney disease.
$0.9403
Pre-market−0.08 (−7.81%)
At close$1.02(+3.39%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.88
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$14.94−$6.33−$7.01−$7.08−$1.65−$2.71−$0.87Pending
Estimate−$9.60−$20.64−$4.46−$5.36−$3.66−$1.15−$0.88−$0.88
Surprise−55.6%+69.3%−57.2%−32.1%+54.9%−135.7%+0.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$27.0K——————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.88 | — | — |
| Aug 2026 | −$0.88 | −$0.87 | +0.6% |
| May 2026 | −$1.15 | −$2.71 | −135.7% |
| Feb 2026 | −$3.66 | −$1.65 | +54.9% |
| Nov 2025 | −$5.36 | −$7.08 | −32.1% |
The latest year is open to everyone — the 31 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Apr 2022 | |||
| Oct 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Nov 2018 | |||
| Jul 2018 | — | — | — |
| Apr 2018 | — | — | — |
| Feb 2018 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.88 | — | — | — | — | — | — |
| Aug 7, 2026 | −$0.88 | −$0.87 | +0.6% | — | — | — | −0.9% |
| May 7, 2026 | −$1.15 | −$2.71 | −135.7% | — | — | — | −5.9% |
| Feb 26, 2026 | −$3.66 | −$1.65 | +54.9% | — | — | — | −0.8% |
| Nov 6, 2025 | −$5.36 | −$7.08 | −32.1% | — | — | — | −3.0% |
The latest year is open to everyone — the 31 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 6, 2025 | |||||||
| Nov 8, 2024 | |||||||
| Aug 9, 2024 | |||||||
| May 10, 2024 | |||||||
| Mar 22, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 22, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 16, 2022 | |||||||
| Apr 15, 2022 | |||||||
| Oct 29, 2021 | |||||||
| Aug 23, 2021 | |||||||
| Jun 22, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Nov 16, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Jan 28, 2020 | |||||||
| Oct 24, 2019 | |||||||
| Jul 24, 2019 | |||||||
| Apr 29, 2019 | |||||||
| Jan 29, 2019 | |||||||
| Nov 9, 2018 | |||||||
| Jul 31, 2018 | — | — | — | — | — | — | — |
| Apr 27, 2018 | — | — | — | — | — | — | — |
| Feb 8, 2018 | — | — | — | — | — | — | — |